We analysed factors associated with moderate to severe acute GVHD in 111 patients treated with fludarabinbased reduced intensity conditioning (RIC) and allogeneic haematopoietic stem cell transplantation (HSCT). Most patients had a haematological malignancy. Donors were 97 HLA-A, -B and -DRb1 identical unrelated and 14 HLA-A, -B or -DRb1 allele mismatched unrelated donors. In the univariate analysis, we found ten factors associated with acute GVHD. These were diagnosis (P ¼ 0.06), GVHD prophylaxis with combinations other than CsA þ MTX (P ¼ 0.006), graft nucleated (Po0.001) and CD34 (Po0.001) cell-dose, bidirectional ABO mismatch (P ¼ 0.001), conditioning (P ¼ 0.002), hospital vs home-care (P ¼ 0.06), ATG dose (Po0.001), donor herpes virus serology (P ¼ 0.07) and an immunized female donor to male recipient (P ¼ 0.05). In the multivariate analysis, three factors remained significant: a high CD34 cell dose (Po0.001), low dose (4 mg/kg) ATG (Po0.001), and an immunized female donor to male recipient (Po0.01). Patients receiving a CD34 cell dose X17.0 Â 10 6 per kg had a higher incidence of GVHD, 53.7%, compared to 22.3% in patients receiving a lower dose (P ¼ 0.002). In patients without any of these risk factors (n ¼ 70), the incidence of acute GVHD was 14.1%, while it was 38.0 and 85.0% in patients with one (n ¼ 29) or two (n ¼ 10) risk factors (Po0.001). We concluded that risk factors for acute GVHD using RIC are similar as using myeloablative conditioning.
Introduction
Allogeneic haematopoietic stem cell transplantation (HSCT) is the therapy of choice for many haematological malignancies, bone-marrow failure syndromes, and some inherited metabolic disorders. Main obstacles for success are relapse of the disease, infections and GVHD. The mortality rates increase with increasing grade of GVHD. If factors associated with an increased risk for developing GVHD are known, we will be able to apply more effective immunosuppressive prophylaxis for these patients to hopefully decrease the risk for GVHD. Recently, milder, less toxic, reduced intensity conditioning (RIC) protocols have been introduced. The immune-suppressive effect from the conditioning therapy takes advantage of the anti-leukaemia effect from the graft to kill malignant cells. This strategy makes it possible to transplant patients not suitable for transplantation with conventional high-dose conditioning. Less toxic treatment was thought to cause less tissue damage, less intestinal permeability with a low incidence of acute GVHD. However, GVHD is still a major problem when using reduced intensity therapy with similar incidence to that after conventional myeloablative therapy.
1,2 Risk factors for acute GVHD after HSCT with conventional (high dose) conditioning has been documented in various studies. [3] [4] [5] [6] These factors include type of donor, HLAcompatibility, type of GVHD prophylaxis, age, previous herpes virus infection in recipient and donor, graft source, stem-cell dose and sex mismatch. However, factors associated to GVHD after HSCT using RIC and unrelated donors have not been studied previously. In this study, we analysed factors associated with moderate to severe acute GVHD after RIC HSCT in a single centre. Risk factors for GVHD may differ between sibling and unrelated donor HSCT and should therefore be analysed in separate studies.
Patients and methods

Patients
A total of 111 consecutive patients-61 males and 50 females with a median age of 50 (range 1-67) years-treated with fludarabin (Flu)-based RIC and haematopoietic stemcell transplantation (HSCT) from unrelated donors between 1998 and 2006 at the Karolinska University Hospital were included. Most patients had a haematological malignancy, but 26 patients with a solid tumour and 16 with a non-malignant disorder were also included. Characteristics of patients and donors are displayed in Table 1 .
Donors
Donors were 97 HLA-A, -B and -DRb1 identical unrelated (matched unrelated donor (MUD)) and 14 HLA-A, -B or -DRb1 allele level mismatched unrelated donors. Median age of the donors was 36 (20-63) years. There were 72 male and 39 female donors.
HLA typing
All patients and donors were HLA-typed using highresolution genomic typing technique. 7 
Conditioning
All patients received five to six days of Flu (30 mg/m 2 per day) in combination with various additional treatments such as 2 Gy TBI (n ¼ 12), 8 2 Â 3 Gy fractionated TBI and 60 mg/kg Cy(n ¼ 19), Bu 8 mg/kg (n ¼ 45), 9 120 mg/kg Cy (n ¼ 29) or treosulphan (n ¼ 6). 10 All patients received antithymocyte globuline (ATG) during the conditioning. 11 Three types of ATG were used; 11 95 patients received thymoglobulin (4-8 mg/kg) (Genzyme, Cambridge, MN, USA), 4 patients received ATG-Fresenius (30 mg/kg) (Fresenius, Gra¨felfing, Germany) and 12 patients received Campath (30 mg) (Genzyme). 12 Thymoglobulin at a total dose of 4 mg/kg was considered as 'low-dose ATG' while all others were considered as intermediate-to-high dose. 13 
GVHD prophylaxis
Most patients received CsA and MTX as prophylaxis against GVHD. 14, 15 During the first month, blood CsA levels were kept at 200-300 ng/ml. 16 In the absence of GVHD, CsA was discontinued after 4-6 months. 17, 18 Supportive care As a prophylactic gut-decontamination, the patients received ciprofloxacin 500 mg twice daily in combination with oral amphotericin-B or fluconazole. G-CSF was given to 18 (16%) patients until neutrophil engraftment. 19, 20 The administration of G-CSF was ended in 2001 when an association with increased risk for acute GVHD was found. 21 A total of 23 patients were treated at home during the pancytopenic phase. 20 Stem-cell source PBSC were given to 80 patients and BM was given to 31 patients. 22 Before apheresis, all donors of PBSC were treated with G-CSF (Amgen-Roche Inc., Thousand Oaks, CA, USA) 10 mg/kg per day for 4-6 days subcutaneously once a day.
Diagnosis and treatment of GVHD Acute GVHD was diagnosed on the basis of clinical symptoms and/or biopsies (skin, liver, gastrointestinal tract or oral mucosa) according to standard criteria. 23 The patients were treated for grade I acute GVHD with prednisolone, starting at 2 mg/kg per day, which was tapered after the initial response. 24 In more severe cases, ATG, methylprednisolone, MTX, psoralene and UV light (PUVA) or mesenchymal stem cells were used. 25, 26 Definitions Bacteraemia was defined as the first positive blood culture related to a febrile episode during the first 30 days after transplantation. 27 CMV reactivation was determined with PCR in leucocytes weekly. 28, 29 A female donor is considered immunized if she has received blood transfusions or has been pregnant.
Serology for the four most common herpes viruses (herpes simplex 1, CMV, VZV and EBV) were analysed in patients and donors before HSCT. Patients and donors were categorized according to seropositivity for 0-2 or 3-4 of these herpes viruses.
Statistics
The analysis was performed in January 2007. The probabilities of overall survival were estimated using the method of Kaplan-Meier and compared with the logrank test. 30 The incidence of GVHD was estimated using a non-parametric estimator of cumulative incidence curves. 31 Patients were censored at the time of death, rejection or last follow-up. Death before day 100 without GVHD was considered as a competing event. Predictive analyses for GVHD were based on the proportional hazard model for sub-distribution of competing risk. Univariate and multivariate analyses were then performed using Gray's test and the proportional sub-distribution hazard regression model of Fine and Gray. 32 A stepwise backward procedure was used to construct a set of independent predictors. All predictors with a P-value below 0.10 were considered and sequentially removed if the P-value in the multiple model was above 0.05. All tests were two sided. The type I error rate was fixed at 0.05 for factors potentially associated with time-to-event outcomes. Several factors were analysed in the univariate analysis: patient and donor sex and age, HLAmatch, GVHD prophylaxis, ABO-compatibility, sex-mismatch, diagnoses, disease stage, conditioning, stem-cell source, G-CSF after transplantation, previous herpes virus infections, nucleated and CD34 þ cell dose and home care during the cytopenic phase (Table 2 ). In Table 2 relative hazard (RH) and 95% confidence interval (CI) are presented. Analyses were performed using the cmprsk package (developed by Gray, June 2001), Splus 6.2 software and Statistica software. The Mann-Whitney U-test was used to compare continuous variables and the w 2 method was used to compare the distribution of categorical variables.
Results
Acute GVHD A total of 54 patients (49%) did not develop any clinical signs of acute GVHD, 29 (26%) patients developed grade I, 23 (21%) patients had grade II and 5 (4.5%) had grades III-IV acute GVHD. The cumulative incidence of acute GVHD grades II-IV in the whole group of patients was 27%. The cumulative incidences of transplant-related mortality (TRM) was 19, 28, 47 and 60% in patients without GVHD, with grade I, grade II and grade III-IV acute GVHD (Po0.001). No difference in incidence of Table 2 Results from the univariate analysis of risk factors for acute GVHD II-IV after reduced intensity conditioning and HSCT with unrelated donors Outcome and infections. In the whole study population, the overall survival was 67% at 1 year, and 46% at 3 years. Causes of death were relapse/progression 24 (22%), GVHD 5 (4.5%), infection 17 (15%) and others 6 (5.5%). Bacteraemia during the pancytopenic phase occurred in 26 (23%) patients and CMV infection in 69 (62%) patients.
Risk factors for GVHD
In the univariate analysis, we found 10 factors associated to acute GVHD grades II-IV (Table 2 ). These were other diagnosis than acute leukaemia (P ¼ 0.06), GVHD prophylaxis other than CsA þ MTX (P ¼ 0.006), nucleated (Po0.001) and CD34 (Po0.001) cell doses, bidirectional ABO mismatch (P ¼ 0.001), Flu/Bu conditioning (P ¼ 0.002), hospital vs home-care (P ¼ 0.06), ATG dose (Po0.001), donor herpes virus serology (P ¼ 0.07) and an immunized female donor to male recipient (P ¼ 0.05).
In the backwards elimination multivariate analysis, three factors remained significantly associated to acute GVHD grades II-IV: a high CD34 cell dose (Po0.001), low dose (4 mg/kg) ATG (Po0.001) and an immunized female donor to male recipient (Po0.01) ( Table 3 ). The incidences of acute GVHD in patients with and without these three risk factors are shown in Figures 1a-c. Patients receiving a CD34 cell dose X17.0 Â 10 6 per kg had a significantly higher risk for acute GVHD grades II-IV, 53.7%, compared to 22.3% in patients receiving a lower dose (P ¼ 0.002). In patients without any of these three risk factors (n ¼ 70), the incidence of acute GVHD grades II-IV was 14.1%, while it was 38.0 and 85.0% in patients with one (n ¼ 29) or two (n ¼ 10) risk factors, respectively (Po0.001) (Figure 2) . Table 3 Results from the multivariate analysis of risk factors for acute GVHD II-IV after reduced intensity conditioning and HSCT with unrelated donors Risk factors for GVHD after RIC HSCT M Remberger et al
Discussion
Risk factors for acute GVHD grades II-IV after conventional myeloablative conditioning have been examined in many previous studies. [3] [4] [5] [6] However, little is known if the same factors are applicable when using RIC. In this study, we evaluated risk factors for moderate-to-severe acute GVHD after RIC HSCT and found that three factors were significant in the multivariate analysis.
Several studies have shown that ATG reduces the incidence of GVHD, both in related and unrelated donor transplants, and that this effect is dose dependent. 4, 13, [33] [34] [35] [36] [37] [38] [39] Using conventional conditioning, we previously reported that a very low dose of thymoglobulin (4 mg/kg) increases the incidence of both severe acute GVHD and TRM compared to higher doses. 13 High doses resulted in a low incidence of GVHD but no survival benefit due to an increased risk for infections. ATG is responsible for an in vivo T-cell depletion and removal of most T cells leads not only to a low incidence of GVHD, but also to a reduced GVL effect and impaired immune-reconstitution. Based on these data, we currently use an intermediate dose of thymoglobulin (6 mg/kg) in myeloablative transplants. In the present study, the results indicate a similar dosedependant effect of ATG in RIC transplants, as the incidence of acute GVHD is higher in patients receiving 4 mg/kg compared to 6-8 mg/kg (Table 3, Figure 1b ).
An immunized female donor to male recipient was associated to GVHD. A female donor is considered as immunized if she has been pregnant or has received blood transfusions. Probably, the effect is greater if only females immunized against male fetuses or transfusions from a male blood donor are considered, but this information was not available. A previous study from the IBMTR by Gale et al. 3 showed that an alloimmune female donor for a male recipient was the strongest predictor of acute GVHD and this is confirmed in our study. This factor has also been reported significant for de novo chronic GVHD. 40 When transplanting T cells from a female donor, cells that are pre-activated against the Y chromosome to a male recipient may increase the risk for immunological events like GVHD.
In the univariate analysis, both nucleated cell dose and CD34 cell dose were associated with GVHD, but in the multivariate analysis the CD34 cell dose was the strongest factor. The nucleated and CD34 cell dose are strongly correlated to each other (r ¼ 0.76), so if the CD34 cell dose was substituted by the nucleated cell dose in the multivariate analysis, nucleated cell dose was significant (OR 1.04, CI 1.03-1.06, Po0.001). This finding also agrees with a study by Przepiorka et al. 5 who reported a correlation between high CD34 cell dose and acute GVHD. However, in a study in HLA identical siblings by the CIBMTR, high CD34 cell dose by BM or PBSC was not correlated to acute GVHD. 41 Probably the cell dose (nucleated or CD34) is correlated to the number of T cells in the graft. T cells are responsible for GVHD, so a higher number of T cells in the graft is correlated to GVHD is not surprising. Removing the T cells from the graft by T-cell depletion is a most effective way to reduce the incidence of GVHD. [42] [43] [44] Partial in vivo T-cell depletion by ATG reduce the incidence of GVHD in a dose dependent way. 13 Lower doses of ATG leave more donor T cells and are associated to more GVHD compared to when using higher doses of ATG that reduce the number of donor T cells in a higher degree. A threshold level of T cells associated with increased risk of GVHD development has previously been reported after T-cell depletion. 42 In this study, we used in vivo T-cell depletion and it is therefore not surprising that we found a threshold level for CD34 þ cells, if CD34 þ and T-cell levels correlate.
Conditioning with Flu/Bu was associated to a significantly lower incidence of acute GVHD in the univariate analyse ( Table 2 ). The total dose of ATG in the Flu/Bu protocol is 8 mg/kg 9 , while most patients given other protocols received 4-6 mg/kg. The higher dose of ATG given to patients treated with the Flu/Bu protocol probably affected the lower incidence of GVHD, since ATG dose was the strongest factor associated with GVHD in this study. The other individual conditioning protocols were also analysed in both uni-and multivariate analysis. The Flu/Cy protocol was associated to an increased incidence of GVHD in the univariate analysis (Table 2) but in the multivariate analysis no association was seen. In this protocol the majority of the patients (55%) received low dose ATG probably causing the higher incidence of GVHD.
In the univariate analysis, GVHD prophylaxis with CsA and MTX were associated with less GVHD compared to other combinations using CsA þ mycophenolate (MMF) or Prograft þ MMF/MTX/rapamycin (RH 0.34, CI 0.16-0.73, P ¼ 0.006). This is in keeping with a previous study by us. 45 One reason for this may be that only 16% of the patients receiving CsA þ MTX received low dose ATG (4 mg/kg) as compared to 50% of the patients given other combinations.
Some studies have found an association between ABO mismatch and GVHD, 46 but we could not confirm this in our study. Bidirectional ABO blood group mismatch was a significant factor in the univariate analysis but not in the multivariate analysis. Patients with a bidirectional ABO Figure 2 Incidences of acute GVHD grades II-IV in patients with none, one and two of the risk factors found in the multivariate analyse. These risk factors were high CD34 cell dose (X17 Â 10 8 per kg), low dose antithymocyte globuline (ATG) (4 mg/kg) and immunized female donor to male recipient. mismatched donor received a significantly higher CD34 cell dose (P ¼ 0.005), which probably is the reason that this factor failed in the multivariate analysis.
P<0.001
We have previously shown that home-care during the pancytopenic phase is associated with a lower incidence of GVHD. 21 In this study, which only included patients receiving RIC, home-care was significantly associated to GVHD in the univariate analysis but not in the multivariate analysis. More patients treated at home with RIC and unrelated donors are required to evaluate the relative importance of home-care to reduce GVHD compared to the other stronger factors in the multivariate analysis.
Risk factors for acute GVHD using RIC are similar as using myeloablative conditioning, ATG dose and female donor to male recipient. If CD34 cell dose is of importance for GVHD also in patients undergoing myeloablative conditioning may need additional attention.
